GLP-1 injections are a long-term weight loss treatment
Cardiovascular Benefits : The SELECT trials demonstration of cardiovascular risk reduction in non-diabetic obese patients represents a paradigm shift, establishing GLP-1 agonists as potentially life-saving interventions beyond weight loss
There was a steady rise in the use of these drugs in these countries, especially GLP-1R agonists in the U.S., in the periconceptional period
GLP-1 RA has also in the lab shown inhibition of allergic and viral airway inflammation, decreasing airway eosinophilia, mucus production, and airway hyperresponsiveness [94]
Reducing A aggregation/deposition and tau protein hyperphosphorylation Some studies have reported that GLP-1 can affect the pathological process of A deposition and tau hyperphosphorylation (149151)
The Bottom Line Foundayo (orforglipron) is a genuinely novel development in GLP-1 therapy